(4R)-4-ethyl-1,3-oxazolidin-2-one → (R)-3-{4-[4-(3,5-dicyclopropylpyridin-2-yl)piperazine-1-carbonyl]-3-methanesulfonylphenyl}-4-ethyloxazolidin-2-one

HRID 1804239노트

반응식

HRID 1804239 반응식
Br[C:2]1[CH:7]=[CH:6][C:5]([C:8]([N:10]2[CH2:15][CH2:14][N:13]([C:16]3[C:21]([CH:22]4[CH2:24][CH2:23]4)=[CH:20][C:19]([CH:25]4[CH2:27][CH2:26]4)=[CH:18][N:17]=3)[CH2:12][CH2:11]2)=[O:9])=[C:4]([S:28]([CH3:31])(=[O:30])=[O:29])[CH:3]=1.[CH2:32]([C@@H:34]1[CH2:38][O:37][C:36](=[O:39])[NH:35]1)[CH3:33]>>[CH:22]1([C:21]2[C:16]([N:13]3[CH2:14][CH2:15][N:10]([C:8]([C:5]4[CH:6]=[CH:7][C:2]([N:35]5[C@H:34]([CH2:32][CH3:33])[CH2:38][O:37][C:36]5=[O:39])=[CH:3][C:4]=4[S:28]([CH3:31])(=[O:30])=[O:29])=[O:9])[CH2:11][CH2:12]3)=[N:17][CH:18]=[C:19]([CH:25]3[CH2:27][CH2:26]3)[CH:20]=2)[CH2:24][CH2:23]1

참가 물질

3

실험 절차

By reaction and treatment in the same manner as in Example 111 and using (4-bromo-2-methanesulfonylphenyl)[4-(3,5-dicyclopropylpyridin-2-yl)piperazin-1-yl]methanone (400 mg) described in Preparation Example 89 and (R)-4-ethyloxazolidin-2-one (91.3 mg) described in Preparation Example 26, the title compound (109.5 mg) was obtained.

후처리

  1. customBy reaction and treatment in the same manner as in Example 111
  2. customdescribed in Preparation Example 26

출처 및 근거

ORD 기록
ord-3c6cb6391ab0440eb8db0e52161ecdb9
출처 데이터셋
uspto-grants-2013_01
특허 번호
US08354401B2

반응 노트

불러오는 중…